Edwards Lifesciences Price to Free Cash Flow Ratio 2010-2022 | EW

Historical price to free cash flow ratio values for Edwards Lifesciences (EW) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Edwards Lifesciences Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-27 78.14 46.86
2022-09-30 82.63 $1.67 49.55
2022-06-30 95.09 $2.01 47.37
2022-03-31 117.72 $2.27 51.85
2021-12-31 129.55 $2.23 58.15
2021-09-30 113.21 $2.23 50.77
2021-06-30 103.57 $1.66 62.44
2021-03-31 83.64 $1.14 73.64
2020-12-31 91.23 $1.02 89.06
2020-09-30 79.82 $1.09 73.13
2020-06-30 69.11 $1.49 46.47
2020-03-31 62.87 $1.72 36.58
2019-12-31 77.76 $1.46 53.32
2019-09-30 73.30 $1.30 56.21
2019-06-30 61.58 $1.14 54.03
2019-03-31 63.78 $-0.28 0.00
2018-12-31 51.06 $0.27 188.54
2018-09-30 58.03 $0.32 182.38
2018-06-30 48.52 $0.13 369.28
2017-12-31 37.57 $1.29 29.23
2017-09-30 36.44 $1.44 25.24
2017-06-30 39.41 $1.20 32.90
2017-03-31 31.36 $1.22 25.67
2016-12-31 31.23 $1.28 24.33
2018-03-31 46.51 $0.76 60.86
2016-09-30 40.19 $0.70 57.74
2016-06-30 33.24 $0.72 45.94
2016-03-31 29.40 $0.72 40.92
2015-12-31 26.33 $0.68 38.92
2015-09-30 23.70 $0.67 35.32
2015-06-30 23.74 $0.38 62.24
2015-03-31 23.74 $1.34 17.78
2014-12-31 21.23 $1.45 14.66
2014-09-30 17.03 $1.49 11.44
2014-06-30 14.31 $1.68 8.54
2014-03-31 12.36 $0.64 19.45
2013-12-31 10.96 $0.54 20.45
2013-09-30 11.61 $0.50 23.03
2013-06-30 11.20 $0.49 22.89
2013-03-31 13.69 $0.52 26.25
2012-12-31 15.03 $0.36 41.65
2012-09-30 17.90 $0.35 50.77
2012-06-30 17.22 $0.34 50.34
2012-03-31 12.12 $-0.01 0.00
2011-12-31 11.78 $0.16 75.01
2011-09-30 11.88 $0.18 66.74
2011-06-30 14.53 $0.09 170.94
2010-12-31 13.47 $0.27 49.12
2010-09-30 11.18 $0.45 24.68
2010-06-30 9.34 $0.34 27.46
2010-03-31 8.24 $0.46 17.74
2009-12-31 7.24 $0.53 13.76
2011-03-31 14.50 $0.22 67.04
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $48.354B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $226.442B 23.68
Alcon (ALC) Switzerland $36.722B 31.62
STERIS (STE) Ireland $20.456B 25.46
Teleflex (TFX) United States $11.305B 18.34
Fresenius Medical Care AG KGaA (FMS) Germany $10.584B 10.62
Penumbra (PEN) United States $9.289B 2223.46
Globus Medical (GMED) United States $7.506B 38.16
Integer Holdings (ITGR) United States $2.380B 19.11
Glaukos (GKOS) United States $2.298B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.402B 19.97
Paragon 28 (FNA) United States $1.303B 0.00
Nevro (NVRO) United States $1.291B 0.00
Artivion (AORT) United States $0.505B 0.00